发明名称 Advanced methods and systems for treating cell proliferation disorders
摘要 The present invention relates to methods for treating cell proliferation disorders comprising (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated, (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder, and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes.
申请公布号 US8770203(B2) 申请公布日期 2014.07.08
申请号 US200913054279 申请日期 2009.07.14
申请人 Immunolight, LLC.;Duke University 发明人 Bourke, Jr. Frederic A.;Vo Dinh Tuan
分类号 A61N5/00;A61N5/06;A61N5/10 主分类号 A61N5/00
代理机构 Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P. 代理人 Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P.
主权项 1. A method for treating a cell proliferation disorder in a subject, comprising: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated; (2) administering at least one plasmonics-active agent to the subject, (3) applying an initiation energy from an initiation energy source to the subject, wherein the applied initiation energy is enhanced or modified by the plasmonics-active agent, and (4) activating the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, wherein the enhanced or modified energy acts on the activatable pharmaceutical, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation disorder.
地址 Detroit MI US